---
title: 2026 Annual AACR Meeting Posters
description: Explore cutting-edge research on patient-derived organoid technology in oncology drug development. Discover new insights on drug resistance mechanisms and innovative screening platforms for cancer therapies. Speak to an expert today.
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

#### ![](https://resources.huborganoids.nl/hs-fs/hubfs/aacr26.png?width=350&name=aacr26.png)AACR ANNUAL MEETING 2026

# On-demand posters

Thanks for your interest in our research. Here are our latest findings in the area of organoid screening, drug resistance, and ADC development presented during the Annual American Association for Caner Research 2026 event. Reach out to our team to connect with our scientists and discover how we can help you predict patient response and accelerate your oncology drug development pipeline.

[book your meeting](https://resources.huborganoids.nl/aacr26-posters#form)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/assets2026/poster-701-thumb-updated.jpg?width=330&name=poster-701-thumb-updated.jpg)

#### TUMOR HETEROGENEITY

### #701 Patient-derived Organoid Biobanks Preserve Tumor Heterogeneity and Molecular Signatures

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/a4ee7d7d-c423-4dc2-aab4-0b67448e1dab.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/a4ee7d7d-c423-4dc2-aab4-0b67448e1dab)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-699.png?width=330&name=poster-699.png)

#### TUMOR HETEROGENEITY

### #699 Dynamic Adaptation and Heterogeneity in Tumor Patient-Derived Organoids: Insights into Cancer Evolution and Drug Resistance

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/66e8f7aa-d7b5-490b-aa5d-94bf851e4d59.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/66e8f7aa-d7b5-490b-aa5d-94bf851e4d59)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-6404.png?width=330&name=poster-6404.png)

#### ORGANOID SCREENING

### #6404 A Robust Organoid-Based Platform for High-Throughput Screening and Drug Discovery

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/e528265c-a198-4c43-ae3a-65f743d93b20.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/e528265c-a198-4c43-ae3a-65f743d93b20)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-5702.png?width=330&name=poster-5702.png)

#### ADC INTERNALIZATION

### #5702 An Image-based Approach to Visualize ADC Internalization and Cytotoxicity in Patient-derived Organoids

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/60df8a78-a472-4b80-ba01-e73d60f56e8a.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/60df8a78-a472-4b80-ba01-e73d60f56e8a)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-5544.png?width=330&name=poster-5544.png)

#### IMMUNE CEL CO-CULTURE

### #5544 Organoid-PBMC Co-Cultures: A Robust Platform for Bispecific Antibody Immunotherapy Development

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/83040e11-ef44-4a5f-a1db-53be51de6bf9.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/83040e11-ef44-4a5f-a1db-53be51de6bf9)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-3187.png?width=330&name=poster-3187.png)

#### KRAS INHIBITOR TESTING

### #3187 A Patient-derived Organoid Screening Platform as a Powerful Tool to Study Efficacy of KRAS Inhibitors

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/f97261fc-f193-4f87-b60b-f77ae61a64de.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/f97261fc-f193-4f87-b60b-f77ae61a64de)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-3119.png?width=330&name=poster-3119.png)

#### DRUG RESISTANCE

### #3119 Modelling chemotherapy persistence in colorectal cancer using patient-derived organoids

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/e1edd12d-bbb8-4413-b133-40f4c2f15036.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/e1edd12d-bbb8-4413-b133-40f4c2f15036)

![tile-image](https://resources.huborganoids.nl/hs-fs/hubfs/poster-2515.png?width=330&name=poster-2515.png)

#### PRECISION MEDICINE

### #2515 Miniaturizing Patient-derived Organoid Screening Assays for Predictive Drug Testing

[![download poster](https://no-cache.hubspot.com/cta/default/14556940/a1625d1e-4271-445b-8ef1-eb84258cd6ff.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/a1625d1e-4271-445b-8ef1-eb84258cd6ff)

## Curious to know how patient-derived organoid technology can be integrated in your research?

[speak to an expert](https://www.huborganoids.nl/contact/)

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*

M